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In patients with mitral stenosis the need for therapeutic intervention can be assessed by clinical and non-invasive
data. Mitral valve replacement is indicated when marked dyspnoea on mild exertion, dyspnoea at rest or
pulmonary oedema, haemoptysis, atrial fibrillation, recurrent systemic emboli or right ventricular failure occur in
a patient with a mitral valve area of <l-5cm2, as measured by Doppler echocardiography. This treatment will
entail life-long anticoagulation in the majority of patients.
Closed commissurotomy is no longer considered a valid therapeutic alternative due to its limited success rate but
open commissurotomy and balloon valvotomy may be performed in patients with no significant calcification of
valve cusps and no major concomitant mitral regurgitation. Preservation of the subvalvular apparatus and left
ventricular geometry can be considered the most important advantages of these techniques. More severe chronic
symptoms are generally required as indication for mitral valve replacement because of the additional long-term
imponderabilities imposed by an implanted artificial device. Therefore, in patients with mitral stenosis different
symptoms and clinical findings will eventually lead to different interventions.
Introduction
Since Bailey's first report of closed commissurotomy
in 19491'1 several procedures, such as open commis-
surotomy, mitral valve replacement and lately
percutaneous mitral balloon valvotomy have been
advocated as interventions in patients with significant
mitral stenosis. Each procedure has its own
indications and merits which shall be discussed in this
report.
Natural history of mitral stenosis
Following an episode of rheumatic fever patients
with mitra] stenosis are usually asymptomatic for 10 to
20 years. When symptoms first appear about another 5
to 10 years will pass until disabling symptoms
develop121. Once major symptoms are present life
expectancy is shortened and 5-year survival is 62% in
patients with NYHA class III symptoms and only 15%
with NYHA class IV"'4' (Fig. 1). Furthermore, a
one-year mortality rate of close to 50% was reported
by Rapaport"1 in patients with mitral stenosis
developing congestive right heart failure. The most
common causes of death are pulmonary oedema,
pulmonary hypertension with right ventricular failure,
systemic embolism and infective endocarditis.
Haemodynamic background of symptoms in mitral
stenosis
With increasing obstruction of the mitral valve there
is a concomitant rise in left atrial pressure, and in
patients with mitral stenosis a close correlation
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between mitral valve area and symptomatology can be
observed, although some variability in exercise
tolerance in patients with the same degree of stenosis
is not an infrequent finding (Table 1). If left atrial and
pulmonary capillary pressures exceed 30 mmHg,
capillary hydrostatic pressures exceed oncotic press-
ures resulting in transudation of plasma into the
intrastitial tissue and the intra-alveolar space leading to
marked shortness of breath and pulmonary oedema.
This mechanism is accentuated by exercise since a
two-fold increase in mitral flow produces a four-fold
increase in pressure-gradient across the valve.
Accordingly, left atrial pressure rises steeply during
exercise. The mechanism preventing pulmonary
capillary pressures rising above pulmonary oedema
level is reduction in diastolic mitral flow and cardiac
output. This reduction in flow and cardiac output is
accomplished by an increase in pulmonary vascular
tone within the smaller arteriolar branches of the
pulmonary circulation leading to active pulmonary
hypertension. The resulting low cardiac output is
responsible for symptoms such as increased fatigue
and a marked decrease in exercise tolerance.
Furthermore, chronic elevation of pressures within the
left atrium will lead to dilatation and finally to atrial
fibrillation. Chronic, permanent atrial fibrillation is
generally not seen until mitral stenosis is hemodynam-
ically significant.
Data from the Framingham study1" showed that the
cerebrovascular accident rate was increased six-fold
with isolated atrial fibrillation and 18-fold when atrial
fibrillation was associated with mitral valve disease.
Since most of these cerebro-vascular accidents were
due to embolism, it is not surprising that in 43% of
patients with significant mitral stenosis and in 8-5% of
patients with mitral regurgitation left atrial thrombi
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Figure 1 National history of mitral stenosis.
Table 1 Mitral valve area (MVA) and symptomatic status in
patients with mitral stenosis
MVA (cm2) Symptoms
>2-0 Asymptomatic at rest and during exercise
2-0-1 -5 Asymptomatic at rest; shortness of breath
during heavy exercise
1-5-1-2 a- or oligo-symptomatic at rest; shortness of
breath with mild exercise
<l-2 Nocturnal cough, PND, orthopnoea,
haemoptysis, RV failure.
PND, paroxysmal nocturnal dyspnoea, RV = right ventricular.
were found during surgery121. Approximately 20% of
patients with rheumatic mitral valve disease ex-
perience systemic embolization at some time during
the course of the illness and in 25% the embolism is
recurrent"1. Fifty percent of detected emboli appear in
the cerebral circulation.
With regard to natural history and haemodynamics
the following signs and symptoms are of clinical
importance in patients with mitral stenosis: marked
shortness of breath with mild exercise, paroxysmal
nocturnal dyspnoea, orthopnoea, history of pulmo-
nary oedema, haemoptysis, increased fatigue, marked
decrease in exercise tolerance, systemic embolism,
right ventricular failure and atrial fibrillation.
Indications for interventions in patients with mitral
stenosis
Signs and symptoms in which an intervention should
be considered in patients with mitral stenosis are listed
in the following section with their causes in
parentheses. Asymptomatic patients with the clinical
picture of mitral stenosis should undergo exercise
testing in order to objectively assess their exercise
tolerance.
(A) SYMPTOMS
These comprise any form of dyspnoea (elevated
pulmonary capillary wedge pressure). More severe
chronic symptoms are required as indications for
mitral valve replacement than for percutaneous mitral
balloon valvotomy because of the additional long-term
imponderabilities imposed by the artificial device.
Other symptoms include increased fatigue or marked
decrease in exercise tolerance (low cardiac output
with pulmonary arteriolar hypertension); haemoptysis
(pulmonary venous hypertension).
(B) CLINICAL FINDINGS
These comprise systemic embolism (enlargement of
left atrial appendage, atrial fibrillation); signs of right
ventricular failure (pulmonary hypertension); atrial
fibrillation (dilatation of left atrium).
(C) ECHOCARDIOGRAPHIC FINDINGS
These comprise pressure half time (t/2) > 150 ms,
i.e. MVA < 1-5 cm2; mean diastolic pressure gradient
at rest >5 mmHg.
(D) HAEMODYNAMIC DATA
These comprise mean diastolic pressure gradient at
rest >5 mmHg; pulmonary capillary wedge pressure
>20mmHg; systolic pulmonary artery pressure
>50mmHg; mitral valve area <l-5cm2; pulmonary
arteriolar resistance >3 units.
Interventions in patients with significant mitral
stenosis
There are four possible interventions in patients
with haemodynamically significant mitral stenosis: (a)
closed commissurotomy; (b) open commissurotomy;
(c) mitral valve replacement (with mechanical or
bioprosthetic valves); (d) percutaneous mitral balloon
valvotomy.
Comparative studies from Farhat et al.m have
shown that open commissurotomy improved haem-
odynamic values to a greater extent than closed
commissurotomy, both at rest and during exercise.
Therefore, in industrial countries closed commissuro-
tomy is no longer performed and will not be described
in this report. Each of the remaining three procedures
has its advantages (Table 2) and there is a need for
proper patient selection.
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Table 2 Advantages and disadvantages of different procedures in mitral stenosis
Advantages Disadvantages
Open commissurotomy Visualization of valve
opening and subvalvular
apparatus
Preservation of subvalvular
apparatus
Additional surgical
procedures possible
Calcifications and mitral
regurgitation are no
contraindications
Additional surgical
procedures possible
Percutaneous mitral balloon Non-surgical intervention
valvotomy Preservation of sub-valvular
apparatus
Mitral valve replacement
Surgical intervention
Marked calcification and
severe mitral regurgitation
are contraindications
Surgical intervention
Life-long anticoagulation
(with mechanical devices
and/or atrial fibrillation)
Thromboembolic
complications
Heavy calcification and
marked mitral
regurgitation are
contraindications
No visualization of mitral
valve and sub-valvular
apparatus
Additional surgical
procedures not possible
(A) PREREQUISITE FOR OPEN COMMISSUROTOMY181
These comprise (1) Pliable valves (loud S, and
presence of opening snap); (2) Absent or only slight
calcification of mitral valve (reduced risk of
dislodgement of calcific material); (3) Absent or only
slight mitral regurgitation; no severe subvalvular
disease (repair of valvular and subvalvular apparatus
possible); (4) No previous commissurotomy; (5)
Concomitant other valvular heart disease and/or
coronary artery disease.
Left atrial thrombi are no contraindication (reduced
risk of intra-operative embolism).
(B) PREREQUISITE FOR MJTRAL VALVE REPLACEMENT
These comprise (1) Marked calcification of valve;
(2) Moderate to severe concomitant mitral regurgita-
tion; (3) Chronic atrial fibrillation with marked
dilatation of left atrium together with atrial thrombi;
(4) Significant involvement of the subvalvular
apparatus; (5) Concomitant other valvular heart
disease and/or coronary artery disease.
(C) PREREQUISITE FOR PERCUTANEOUS MITRAL
BALLOON VALVOTOMY1"
These comprise (1) Pliable valves (loud S, and
presence of opening snap); (2) Absent or minimal
calcification; (3) Absent or mild mitral regurgitation;
(4) No thrombi in left atrium and no recent previous
thromoembolic events; (5) Absence of other con-
comitant valvular heart disease and/or coronary artery
disease.
Conclusions
In patients with mitral stenosis the need for
therapeutic intervention can be assessed by clinical
and non-invasive data. The indication for a given
intervention depends mainly on the status of the
mitral apparatus, which can best be evaluated by
transoesophageal and transthoracic echocardiography.
Closed commissurotomy is no longer considered a
valid therapeutic alternative due to its limited success
rate but open commisurotomy and balloon valvotomy
may be performed in patients without significant
calcification of valve cusps and no major concomitant
mitral regurgitation. Preservation of the subvalvular
apparatus and left ventricular geometry can be
considered the most important advantages of these
techniques. More severe chronic symptoms and
contraindications either to balloon valvotomy or
commissurotomy are generally required as indications
for mitral valve replacement because of the additional
long-term imponderabilities imposed by an implanted
artificial device. Therefore, in patients with mitral
stenosis different symptoms and clinical findings will
eventually lead to different interventions.
Finally, for certain special indications such as
endstage mitral stenosis, severe pulmonary hyperten-
sion, major involvement of the subvalvular apparatus
or symptomatic mitral stenosis during pregnancy the
optimal type of intervention is still a matter of debate.
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